HIV-vaccine trial halted after review board finds no effect
“These results do not change the fundamental view that an AIDS vaccine remains critical to any long-term strategy to end the AIDS epidemic.”
Matthew Rose, a D.C. participant in the HVTN 505 HIV-vaccine trial, which was halted today. The trial was called off after an independent review board found the vaccine neither prevented HIV infections nor reduced the amount of HIV in people infected with virus. The trial focused specifically on gay and bisexual men, and men who otherwise have sex with men, and transgender people. (Reuters)
Support Metro Weekly’s Journalism
These are challenging times for news organizations. And yet it’s crucial we stay active and provide vital resources and information to both our local readers and the world. So won’t you please take a moment and consider supporting Metro Weekly with a membership? For as little as $5 a month, you can help ensure Metro Weekly magazine and MetroWeekly.com remain free, viable resources as we provide the best, most diverse, culturally-resonant LGBTQ coverage in both the D.C. region and around the world. Memberships come with exclusive perks and discounts, your own personal digital delivery of each week’s magazine (and an archive), access to our Member's Lounge when it launches this fall, and exclusive members-only items like Metro Weekly Membership Mugs and Tote Bags! Check out all our membership levels here and please join us today!
